HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Low Frequencies of Autoimmunity-Associated PTPN22 Polymorphisms in MODY Patients, Including Those Transiently Expressing Islet Cell Autoantibodies.

AbstractBACKGROUND:
The protein tyrosine phosphatase nonreceptor type 22 (PTPN22) gene encodes lymphoid tyrosine phosphatase (LYP), which is expressed primarily in lymphoid tissues. The functional but geographically highly variable PTPN22 single-nucleotide polymorphisms (SNPs), particularly c.1858C>T, contribute to the onset and progression of autoimmunity-associated diseases and facilitate the expression of disease-associated autoantibodies. In Central Europe, 17-25% of patients with monogenic diabetes (maturity-onset diabetes of the young, MODY) transiently express islet cell autoantibodies.
METHODS:
We addressed the links between the functional and geographically variable PTPN22 SNPs with MODY manifestation and the expression of islet cell autoantibodies in 276 MODY patients who originated from four regions (the Czech Republic, Israel, Japan and Brazil).
RESULTS:
The frequency of PTPN22 polymorphisms in the MODY patients was similar to those in geographically matched healthy populations, with the exception of c.788G>A, the minor allele frequency of which was significantly elevated in the Czech hepatocyte nuclear factor 1-α (HNF1A) MODY patients [odds ratio (OR) 4.8, 95% confidence interval (CI) 2.2-10.7] and the Brazilian MODY patients (OR 8.4, 95% CI 1.8-39.1). A barely significant increase in the c.788G>A minor allele was also detected in the islet cell autoantibody-positive Czech MODY patients. However, c.788A behaves as a loss-of-function mutant in T cells, and thus protects against autoimmunity.
CONCLUSIONS:
MODY patients (including islet cell autoantibody-positive cases) do not display any increase in autoimmunity-associated PTPN22 alleles. The absence of autoimmunity-associated PTPN22 alleles was also demonstrated in latent autoimmune diabetes in adults, which suggests that the slow kinetics of the onset of autoantibodies is subject to a regulation that is different from that experienced in type 1 diabetes and other autoimmune disorders.
AuthorsPetr Heneberg, Milena Malá, Tohru Yorifuji, Galia Gat-Yablonski, Yael Lebenthal, Toshihiro Tajima, Viviane Nogaroto, Blanka Rypáčková, Lucie Kocková, Jana Urbanová, Michal Anděl
JournalInternational archives of allergy and immunology (Int Arch Allergy Immunol) Vol. 166 Issue 3 Pg. 189-98 ( 2015) ISSN: 1423-0097 [Electronic] Switzerland
PMID25896041 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2015 S. Karger AG, Basel.
Chemical References
  • Autoantibodies
  • PTPN22 protein, human
  • Protein Tyrosine Phosphatase, Non-Receptor Type 22
Topics
  • Adult
  • Autoantibodies (blood)
  • Autoimmune Diseases (genetics, immunology)
  • Autoimmunity (genetics, immunology)
  • Brazil
  • Czech Republic
  • Diabetes Mellitus, Type 2 (genetics, immunology)
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Islets of Langerhans (cytology, immunology)
  • Israel
  • Japan
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide
  • Protein Tyrosine Phosphatase, Non-Receptor Type 22 (genetics)
  • T-Lymphocytes (immunology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: